Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
NYSE:BDX's Cash to Debt is ranked lower than
86% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NYSE:BDX: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BDX' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.52 Max: 1.03
Current: 0.17
0.04
1.03
Equity to Asset 0.31
NYSE:BDX's Equity to Asset is ranked lower than
85% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NYSE:BDX: 0.31 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BDX' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.48 Max: 0.63
Current: 0.31
0.25
0.63
Interest Coverage 4.16
NYSE:BDX's Interest Coverage is ranked lower than
86% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NYSE:BDX: 4.16 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BDX' s Interest Coverage Range Over the Past 10 Years
Min: 2.89  Med: 18.56 Max: 42.29
Current: 4.16
2.89
42.29
F-Score: 6
Z-Score: 2.76
M-Score: -2.73
WACC vs ROIC
8.05%
8.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.23
NYSE:BDX's Operating margin (%) is ranked higher than
73% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NYSE:BDX: 13.23 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BDX' s Operating margin (%) Range Over the Past 10 Years
Min: 10.45  Med: 20.05 Max: 22.75
Current: 13.23
10.45
22.75
Net-margin (%) 9.24
NYSE:BDX's Net-margin (%) is ranked higher than
71% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NYSE:BDX: 9.24 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BDX' s Net-margin (%) Range Over the Past 10 Years
Min: 6.76  Med: 15.56 Max: 18.49
Current: 9.24
6.76
18.49
ROE (%) 15.24
NYSE:BDX's ROE (%) is ranked higher than
81% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NYSE:BDX: 15.24 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BDX' s ROE (%) Range Over the Past 10 Years
Min: 11.38  Med: 24.34 Max: 28.17
Current: 15.24
11.38
28.17
ROA (%) 4.30
NYSE:BDX's ROA (%) is ranked higher than
61% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NYSE:BDX: 4.30 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BDX' s ROA (%) Range Over the Past 10 Years
Min: 3.54  Med: 12.1 Max: 14.79
Current: 4.3
3.54
14.79
ROC (Joel Greenblatt) (%) 29.22
NYSE:BDX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NYSE:BDX: 29.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 20.93  Med: 37.15 Max: 41.46
Current: 29.22
20.93
41.46
Revenue Growth (3Y)(%) 10.40
NYSE:BDX's Revenue Growth (3Y)(%) is ranked higher than
79% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NYSE:BDX: 10.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.4  Med: 8.4 Max: 11.9
Current: 10.4
4.4
11.9
EBITDA Growth (3Y)(%) -1.60
NYSE:BDX's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NYSE:BDX: -1.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.6  Med: 9 Max: 15.7
Current: -1.6
-1.6
15.7
EPS Growth (3Y)(%) -14.20
NYSE:BDX's EPS Growth (3Y)(%) is ranked lower than
74% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NYSE:BDX: -14.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.2  Med: 11.4 Max: 21.9
Current: -14.2
-14.2
21.9
» NYSE:BDX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BDX Guru Trades in Q3 2015

Tom Gayner 4,000 sh (New)
T Rowe Price Equity Income Fund 210,000 sh (New)
George Soros 3,700 sh (New)
Robert Olstein 65,000 sh (+32.65%)
Ken Fisher 1,989 sh (+20.11%)
First Eagle Investment 1,370,041 sh (+4.67%)
John Hussman 50,000 sh (unchged)
Vanguard Health Care Fund 3,075,487 sh (unchged)
Richard Pzena 373,824 sh (unchged)
Mairs and Power 5,217 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 30,075 sh (-0.33%)
Pioneer Investments 934,559 sh (-0.34%)
Dodge & Cox 15,038 sh (-1.31%)
Jim Simons 1,621,017 sh (-11.39%)
Mario Gabelli 262,443 sh (-19.25%)
Jeremy Grantham 846,445 sh (-22.86%)
Steven Cohen 137,900 sh (-60.17%)
Ray Dalio 5,469 sh (-64.39%)
Paul Tudor Jones 1,700 sh (-64.58%)
» More
Q4 2015

BDX Guru Trades in Q4 2015

Joel Greenblatt 79,016 sh (New)
Tom Gayner 9,000 sh (+125.00%)
T Rowe Price Equity Income Fund 357,800 sh (+70.38%)
Ken Fisher 2,813 sh (+41.43%)
Pioneer Investments 953,254 sh (+2.00%)
First Eagle Investment 1,373,241 sh (+0.23%)
Robert Olstein 65,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Richard Pzena Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Mairs and Power 5,184 sh (-0.63%)
Dodge & Cox 14,780 sh (-1.72%)
Vanguard Health Care Fund 2,937,587 sh (-4.48%)
Ray Dalio 5,069 sh (-7.31%)
Jeremy Grantham 749,694 sh (-11.43%)
Jeff Auxier 26,225 sh (-12.80%)
Mario Gabelli 214,955 sh (-18.09%)
Jim Simons 1,207,317 sh (-25.52%)
» More
Q1 2016

BDX Guru Trades in Q1 2016

Paul Tudor Jones 2,300 sh (New)
Ray Dalio 10,937 sh (+115.76%)
T Rowe Price Equity Income Fund 732,099 sh (+104.61%)
First Eagle Investment 1,389,002 sh (+1.15%)
Dodge & Cox 14,930 sh (+1.01%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
Pioneer Investments 931,609 sh (-2.27%)
Vanguard Health Care Fund 2,703,387 sh (-7.97%)
Mario Gabelli 191,090 sh (-11.10%)
Mairs and Power 4,584 sh (-11.57%)
Robert Olstein 54,000 sh (-16.92%)
Jeremy Grantham 602,775 sh (-19.60%)
Jim Simons 754,966 sh (-37.47%)
Ken Fisher 1,473 sh (-47.64%)
John Hussman 25,000 sh (-50.00%)
Joel Greenblatt 19,575 sh (-75.23%)
» More
Q2 2016

BDX Guru Trades in Q2 2016

Louis Moore Bacon 2,163 sh (New)
Paul Tudor Jones 3,201 sh (+39.17%)
Jeremy Grantham 709,700 sh (+17.74%)
T Rowe Price Equity Income Fund 860,000 sh (+17.47%)
Mairs and Power 4,703 sh (+2.60%)
John Hussman 25,000 sh (unchged)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
Pioneer Investments 917,916 sh (-1.47%)
Joel Greenblatt 18,713 sh (-4.40%)
Ken Fisher 1,395 sh (-5.30%)
Dodge & Cox 13,830 sh (-7.37%)
Mario Gabelli 162,864 sh (-14.77%)
Robert Olstein 46,000 sh (-14.81%)
Vanguard Health Care Fund 1,868,387 sh (-30.89%)
Ray Dalio 3,737 sh (-65.83%)
First Eagle Investment 390,407 sh (-71.89%)
Jim Simons 119,010 sh (-84.24%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:ESLOY, NAS:ILMN, NYSE:BAX, NYSE:BCR, OTCPK:CLPBY, OTCPK:TRUMY, NAS:XRAY, NYSE:WAT, OTCPK:OCPNY, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, NYSE:STE, NAS:SIRO, OTCPK:SAUHF, NYSE:WST, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN » details
Traded in other countries:BOX.Germany, BDX.Switzerland, 0R19.UK,
Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Becton Dickinson & Co was incorporated under the laws of the State of New Jersey in November 1906. The Company is a medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, general public and the pharmaceutical industry. Its operations include three business segments; BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces an array of medical devices that are used in a range of healthcare settings. It includes the safety-engineered injection, infusion and surgery products. BD Medical's product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefill able drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; and sharps disposal containers. BD Diagnostics provide products for the safe collection and transport of diagnostic specimens, as well as instrument systems and reagents to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics' products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to understand disease processes. BD Biosciences' product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks. The products sold by BD outside the United States are needles and syringes; insulin syringes and pen needles; diagnostic systems; BD Vacutainer brand blood collection products; BD Hypak brand prefillable syringe systems; infusion therapy products; flow cytometry instruments and reagents; and disposable laboratory products. It has manufacturing operations outside the United States, Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, t

Ratios

vs
industry
vs
history
P/E(ttm) 34.19
BDX's P/E(ttm) is ranked lower than
63% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.50 vs. BDX: 34.19 )
Ranked among companies with meaningful P/E(ttm) only.
BDX' s P/E(ttm) Range Over the Past 10 Years
Min: 10.27  Med: 19.06 Max: 47.83
Current: 34.19
10.27
47.83
Forward P/E 18.94
BDX's Forward P/E is ranked higher than
81% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. BDX: 18.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.19
BDX's PE(NRI) is ranked lower than
65% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.80 vs. BDX: 34.19 )
Ranked among companies with meaningful PE(NRI) only.
BDX' s PE(NRI) Range Over the Past 10 Years
Min: 13.02  Med: 20.64 Max: 47.83
Current: 34.19
13.02
47.83
Price/Owner Earnings (ttm) 23.52
BDX's Price/Owner Earnings (ttm) is ranked higher than
59% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. BDX: 23.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BDX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.59  Med: 17.72 Max: 38.44
Current: 23.52
10.59
38.44
P/B 4.76
BDX's P/B is ranked lower than
65% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. BDX: 4.76 )
Ranked among companies with meaningful P/B only.
BDX' s P/B Range Over the Past 10 Years
Min: 2.96  Med: 4.09 Max: 5.59
Current: 4.76
2.96
5.59
P/S 3.13
BDX's P/S is ranked higher than
50% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BDX: 3.13 )
Ranked among companies with meaningful P/S only.
BDX' s P/S Range Over the Past 10 Years
Min: 2  Med: 2.72 Max: 3.54
Current: 3.13
2
3.54
PFCF 20.40
BDX's PFCF is ranked higher than
70% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. BDX: 20.40 )
Ranked among companies with meaningful PFCF only.
BDX' s PFCF Range Over the Past 10 Years
Min: 13.46  Med: 19.4 Max: 35.11
Current: 20.4
13.46
35.11
POCF 15.19
BDX's POCF is ranked higher than
60% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. BDX: 15.19 )
Ranked among companies with meaningful POCF only.
BDX' s POCF Range Over the Past 10 Years
Min: 8.76  Med: 12.35 Max: 19.45
Current: 15.19
8.76
19.45
EV-to-EBIT 29.21
BDX's EV-to-EBIT is ranked lower than
69% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. BDX: 29.21 )
Ranked among companies with meaningful EV-to-EBIT only.
BDX' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 13.85 Max: 40.4
Current: 29.21
9.7
40.4
EV-to-EBITDA 17.16
BDX's EV-to-EBITDA is ranked higher than
53% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. BDX: 17.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.5  Med: 10.4 Max: 22.6
Current: 17.16
7.5
22.6
PEG 14.25
BDX's PEG is ranked lower than
94% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. BDX: 14.25 )
Ranked among companies with meaningful PEG only.
BDX' s PEG Range Over the Past 10 Years
Min: 0.92  Med: 1.8 Max: 24.28
Current: 14.25
0.92
24.28
Shiller P/E 33.11
BDX's Shiller P/E is ranked higher than
65% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. BDX: 33.11 )
Ranked among companies with meaningful Shiller P/E only.
BDX' s Shiller P/E Range Over the Past 10 Years
Min: 17.15  Med: 24.35 Max: 39.96
Current: 33.11
17.15
39.96
Current Ratio 1.55
BDX's Current Ratio is ranked lower than
76% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. BDX: 1.55 )
Ranked among companies with meaningful Current Ratio only.
BDX' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.12 Max: 5.82
Current: 1.55
1.17
5.82
Quick Ratio 1.11
BDX's Quick Ratio is ranked lower than
71% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BDX: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
BDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.47 Max: 5.1
Current: 1.11
0.7
5.1
Days Inventory 109.26
BDX's Days Inventory is ranked higher than
60% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. BDX: 109.26 )
Ranked among companies with meaningful Days Inventory only.
BDX' s Days Inventory Range Over the Past 10 Years
Min: 107.91  Med: 120.58 Max: 127.55
Current: 109.26
107.91
127.55
Days Sales Outstanding 47.97
BDX's Days Sales Outstanding is ranked higher than
76% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. BDX: 47.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.97  Med: 58.29 Max: 62.16
Current: 47.97
47.97
62.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.47
BDX's Dividend Yield is ranked higher than
57% of the 136 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.29 vs. BDX: 1.47 )
Ranked among companies with meaningful Dividend Yield only.
BDX' s Dividend Yield Range Over the Past 10 Years
Min: 1.12  Med: 1.77 Max: 2.44
Current: 1.47
1.12
2.44
Dividend Payout 0.49
BDX's Dividend Payout is ranked lower than
70% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BDX: 0.49 )
Ranked among companies with meaningful Dividend Payout only.
BDX' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.29 Max: 2.07
Current: 0.49
0.16
2.07
Dividend Growth (3y) 10.10
BDX's Dividend Growth (3y) is ranked lower than
52% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. BDX: 10.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BDX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 2.6  Med: 12.9 Max: 29.1
Current: 10.1
2.6
29.1
Forward Dividend Yield 1.47
BDX's Forward Dividend Yield is ranked higher than
54% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BDX: 1.47 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.39
BDX's Yield on cost (5-Year) is ranked higher than
69% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. BDX: 2.39 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BDX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.81  Med: 2.86 Max: 3.95
Current: 2.39
1.81
3.95
3-Year Average Share Buyback Ratio -2.30
BDX's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. BDX: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.3  Med: 0.8 Max: 6
Current: -2.3
-2.3
6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.76
BDX's Price/Projected FCF is ranked higher than
56% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. BDX: 1.76 )
Ranked among companies with meaningful Price/Projected FCF only.
BDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.47 Max: 3.81
Current: 1.76
0.99
3.81
Price/DCF (Earnings Based) 3.20
BDX's Price/DCF (Earnings Based) is ranked lower than
65% of the 17 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.08 vs. BDX: 3.20 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.15
BDX's Price/Median PS Value is ranked higher than
55% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. BDX: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
BDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.7  Med: 0.95 Max: 1.29
Current: 1.15
0.7
1.29
Earnings Yield (Greenblatt) (%) 3.40
BDX's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. BDX: 3.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 7.2 Max: 10.4
Current: 3.4
2.5
10.4
Forward Rate of Return (Yacktman) (%) 6.18
BDX's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. BDX: 6.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BDX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5.3  Med: 14.8 Max: 19.6
Current: 6.18
5.3
19.6

More Statistics

Revenue (TTM) (Mil) $12,311
EPS (TTM) $ 5.25
Beta0.98
Short Percentage of Float1.52%
52-Week Range $128.87 - 181.76
Shares Outstanding (Mil)212.93

Analyst Estimate

Sep16 Sep17 Sep18
Revenue (Mil $) 12,531 12,553 12,812
EPS ($) 8.46 9.51 10.46
EPS w/o NRI ($) 8.46 9.51 10.46
EPS Growth Rate
(3Y to 5Y Estimate)
10.46%
Dividends Per Share ($) 2.66 2.93 3.18
» More Articles for NYSE:BDX

Headlines

Articles On GuruFocus.com
The 10 Best Dividend Aristocrats Aug 15 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Mawer Investment Newsletter 2nd Quarter 2016 Jul 15 2016 
Becton Dickinson: 19% EPS Growth With Good Dividends Jun 26 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Weekly 52-Week Highs Highlights Apr 27 2016 
Mario Gabelli Sells Alphabet, AT&T Mar 17 2016 
Richard Pzena Buys Chevron During 4th Quarter Feb 10 2016 
Mawer Investment Newsletter 4th Quarter 2015 Jan 25 2016 
A Recession-Resistant Dividend Aristocrat With 10% Dividend Growth Jan 05 2016 

More From Other Websites
Twilio Inc (TWLO), Alphabet Inc (GOOGL) and More: These 5 Stocks Are Dominating the Charts Sep 23 2016
Becton (BDX) to Expand Syringe Capacity at Holdrege Facility Sep 23 2016
Becton Dickinson downgraded by Citigroup Sep 23 2016
Becton, Dickinson (BDX) Launch Wireless Diagnostic Device Sep 22 2016
BD Invests $100 Million In Nebraska Plant To Expand Insulin Syringe Manufacturing Sep 22 2016
BD Invests $100 Million In Nebraska Plant To Expand Insulin Syringe Manufacturing Sep 22 2016
BD Unveils Next Generation Wireless Point-of-Care Diagnostic Device Sep 21 2016
BD Unveils Next Generation Wireless Point-of-Care Diagnostic Device Sep 21 2016
Becton, Dickinson & Co. – Value Analysis (NYSE:BDX) : September 19, 2016 Sep 19 2016
Becton, Dickinson (BDX) Introduces New Vascular Dressing Sep 19 2016
BD Submits Pre-Market Approval Application to FDA for BD Onclarity™ HPV Test Sep 17 2016
ETF’s with exposure to Becton, Dickinson & Co. : September 16, 2016 Sep 16 2016
Becton, Dickinson & Co. breached its 50 day moving average in a Bullish Manner : BDX-US : September... Sep 16 2016
BD and Vancive Medical Technologies Launch New Vascular Dressings with CHG Antimicrobial Sep 16 2016
BD and Vancive Medical Technologies Launch New Vascular Dressings with CHG Antimicrobial Sep 16 2016
Becton, Dickinson (BDX) Gets USFDA Clearance for BD MAX Sep 15 2016
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions Sep 14 2016
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions Sep 14 2016
Current report no 62 / 2016 Sep 13 2016
BD Announces New Software Release For Pyxis Enterprise Solution Sep 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)